🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. A study in healthy people to test whether erythromycin influences the amount of BI 1291583 in the blood.

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  2. A study in healthy volunteers to find out how long aticaprant stays in and acts on the body when administered with or without food and with or without fluconazole

    Janssen-Cilag International N.V.

    Healthy Adult Participants

    phase 1 other active

    1 trial

  3. A study in healthy volunteers to find out how long aticaprant stays in and acts on the body when administered with or without rabeprazole.

    Janssen-Cilag International N.V.

    Healthy Adult Participants.

    phase 1 other active

    1 trial

  4. A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helps

    Boehringer Ingelheim

    Melanoma, Solid tumours

    phase 1 other active

    1 trial

  5. A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a CYP3 inhibitor

    Boehringer Ingelheim

    Solid cancer tumors

    phase 1 other active

    1 trial

  6. A study in subjects with gout flares that investigates the effect, safety, tolerability, and pharmacokinetics (absorption, distribution, metabolism, and elimination) of a single dose of LEO 158968, a new compound that may potentially be used in the treatment of several autoinflammatory diseases

    LEO Pharma A/S

    Gout flares

    phase 1 other active

    1 trial

  7. A study investigating the effect of different approved medications on how the body processes the study compound RO7795081. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control.

    Hoffmann-La Roche

    Type 2 Diabetes and obesity

    phase 1 other active

    1 trial

  8. A study investigating the safety of RO7795081 and the effect of RO7795081 on how the body processes different approved medications. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

    Hoffmann-La Roche

    Obesity or Overweight

    phase 1 other active

    1 trial

  9. A study investigating the safety, absorption, and elimination of NNC0705-0001, a new compound that could potentially be used in the treatment of cardiometabolic diseases caused by inflammation.

    NovoThirteen

    Cardiometabolic diseases with an inflammatory component

    phase 1 other active

    1 trial

  10. A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  11. A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

    Hoffmann-La Roche

    Healthy volunteers

    phase 1 other active

    1 trial

  12. A study investigating the safety, absorption, and elimination of RO7795081, a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  13. A study investigating the safety, absorption, and elimination of radioactively labeled RO7269162, a new compound that may potentially be used in the treatment of Alzheimer’s disease.

    Hoffmann-La Roche

    Healthy males volunteers

    phase 1 other active

    1 trial

  14. A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria.

    Novartis Pharmaceuticals

    Malaria

    phase 1 other active

    1 trial

  15. A study to assess how radium-223 moves through the patients with prostate cancer receiving radium-223 dichloride treatment.

    Bayer AG

    Prostate cancer

    phase 1 other active

    1 trial

  16. A study to assess the safety, and blood levels of CTX-187 after single and repeated intravenous doses in healthy volunteers and patients with bacterial infection

    Centauri Biotech SL

    Bacterial Infection

    phase 1 other active

    1 trial

  17. A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of Etentamig (ABBV-383) in patients with relapsed or refractory Multiple Myeloma

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or Refractory Multiple Myeloma (R/R MM)

    phase 1 other active

    1 trial

  18. A study to compare the amount of milvexian in blood when given as pediatric and adult tablet formulations, to assess the effect of food intake on the absorption of pediatric milvexian tablet formulation in healthy adult participants and to assess the acceptability of different milvexian formulations.

    Janssen-Cilag International N.V.

    atherothrombotic and thromboembolic disorders

    phase 1 other active

    1 trial

  19. A study to find out how healthy people tolerate a new drug called S221237.

    The George Institute

    Parkinson disease (PD)

    phase 1 other active

    1 trial

  20. A study to find out whether the medication pasireotide is absorbed and processed the same way when given under the skin using either a reusable pen or a syringe in healthy subjects

    Recordati Ireland

    Post-bariatric hypoglycaemia

    phase 1 other active

    1 trial

  21. A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma

    Oncopeptides AB (publ)

    Recurrent glioblastoma

    phase 1 other active

    1 trial

  22. A study to investigate the safety and efficacy of SAR446523 injected subcutaneously in adult participants with relapsed/refractory myeloma

    Sanofi-aventis Healthcare Pty Ltd

    Plasma cell myeloma refractory

    phase 1 other active

    1 trial

  23. A study to investigate the safety and pharmacological effect of a single intravenous infusion of GSK2857914 in male and female participants aged 18 to 75 with moderate to severe systemic lupus erythematosus

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  24. A study to investigate the safety and tolerability of Trastuzumab Deruxtecan in combination with Immunotherapy Agents with and without chemotherapy, as the first treatment option for patients with advanced HER2 over-expressing Non-Small Cell Lung Cancer.

    AstraZeneca AB

    Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) with human epidermal growth factor receptor 2 (HER2) overexpression (OE)

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources